SpringWorks enters up to $250M ATM equity offering program with Cowen

SpringWorks Therapeutics, Inc.

Sales Agreement with Cowen and Company allows sales of common stock up to $250 million aggregate offering price.
Shares sold through Nasdaq or other existing trading markets; 3.0% commission paid to Cowen.
Offering made under prior S-3 registration statement; prospectus supplement filed February 27, 2024.
No minimum sales required; Agent uses commercially reasonable efforts based on Company instructions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

SpringWorks Therapeutics, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at $250 million (effective 2024-02-27).

Action: entry
Agreement: atm program
Counterparty: Cowen and Company, LLC
Value: $250 million
Effective: 2024-02-27

Exact text from the filing

On February 27, 2024, SpringWorks Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC, serving as sales agent (the “Agent”) with respect to an at the market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $250 million (the “Shares”) through the Agent (the “Offering”).

View on SEC.gov

755 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001104659-24-027933

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.